

Evidence-Based Management of Pediatric Atopic Dermatitis: A Comprehensive Review Incorporating Recent Guideline and Therapeutic Advances

Muhammad Asim, MRCPCH¹*, Mazher Iqbal¹

¹Department of Pediatrics, Midhnab General Hospital, Qassim, Saudi Arabia.

*Corresponding Author: Dr. Muhammad Asim, MRCPCH, Department of Pediatrics, Midhnab General Hospital, Qassim, Saudi Arabia.

<https://doi.org/10.58624/SVOAPD.2026.05.021>

Received: May 20, 2026

Published: July 25, 2026

Citation: Asim M, Iqbal M. Evidence-Based Management of Pediatric Atopic Dermatitis: A Comprehensive Review Incorporating Recent Guideline and Therapeutic Advances *SVOA Paediatrics* 2026, 5:4, 140-145. doi: 10.58624/SVOAPD.2026.05.021

Abstract

Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder affecting children worldwide and significantly impacting quality of life, sleep, psychosocial well-being, and family functioning.

Objective: To provide a comprehensive evidence-based review of pediatric atopic dermatitis management incorporating recent guideline recommendations and advances in targeted therapies.

Methods: A structured literature review was conducted using PubMed, Google Scholar, NICE, WHO, AAP, and international dermatology guideline publications from 2018 to 2025. Search terms included “pediatric atopic dermatitis,” “eczema,” “dupilumab,” “JAK inhibitors,” “biologics,” and “guidelines.” Relevant systematic reviews, randomized controlled trials, cohort studies, and guideline documents focusing on pediatric populations were included.

Results: Management strategies include optimized skin care, topical anti-inflammatory therapies, phototherapy, systemic immunomodulators, biologics, and Janus kinase (JAK) inhibitors. Recent advances in biologic and targeted therapies have significantly improved disease control and quality of life in moderate-to-severe disease.

Conclusion: Pediatric atopic dermatitis requires a stepwise, individualized, and multidisciplinary approach. Integration of evidence-based skin care, topical therapy, and emerging targeted treatments improves disease outcomes and may influence long-term progression of atopic disease.

Keywords: Atopic Dermatitis; Eczema; Pediatric Dermatology; Biologics; Dupilumab; JAK Inhibitors; Topical Therapy.

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting a significant proportion of children worldwide, with increasing prevalence in both developed and developing countries [1,2]. It is characterized by pruritus, xerosis, recurrent eczematous lesions, and relapsing disease activity that may significantly impair sleep, psychosocial well-being, school performance, and quality of life.

AD is associated with immune dysregulation, particularly involving type 2 inflammatory pathways mediated by interleukin (IL)-4 and IL-13. Skin barrier dysfunction, genetic susceptibility, and environmental triggers contribute to disease development and progression [1].

Recent advances in understanding the immunopathogenesis of AD have led to the development of targeted therapies including biologics and Janus kinase (JAK) inhibitors. Contemporary management now focuses not only on symptom control but also on long-term disease modification, restoration of skin barrier function, prevention of flares, and improvement in patient quality of life [3-5].

Methods

A structured literature review was conducted using PubMed, Google Scholar, NICE, WHO, AAP, and international dermatology guideline publications from 2018 to 2025. Search terms included “pediatric atopic dermatitis,” “eczema,” “dupilumab,” “JAK inhibitors,” “biologics,” and “guidelines.” Relevant systematic reviews, randomized controlled trials, cohort studies, and guideline documents focusing on pediatric populations were included.

Pathophysiology

Atopic dermatitis is characterized by epidermal barrier dysfunction and immune dysregulation involving predominantly type 2 inflammatory pathways. Filaggrin (FLG) mutations, altered ceramide composition, and increased transepidermal water loss contribute to impaired skin barrier integrity and increased susceptibility to allergens, irritants, and microbial colonization [1,6].

Recent studies have also highlighted the role of the skin microbiome in immune priming and disease progression. Alterations in early-life skin bacterial communities may influence later development of atopic dermatitis and impaired skin barrier maturation [7].

Children with AD are also at increased risk of developing other atopic conditions including asthma, allergic rhinitis, and food allergies, a phenomenon commonly described as the “atopic march” [8].

Clinical Features and Burden of Disease

Pediatric atopic dermatitis commonly presents with pruritic, xerotic, and relapsing eczematous lesions with age-dependent distribution patterns. Infants often present with facial and extensor involvement, while older children more commonly develop flexural disease.

The disease burden extends beyond skin manifestations. Sleep disturbance, anxiety, depression, impaired school performance, social stigmatization, and caregiver stress are increasingly recognized consequences of chronic disease activity [9].

The 2025 American Academy of Pediatrics (AAP) update emphasized the substantial psychosocial burden of AD and highlighted the importance of proactive long-term disease control and family-centered care [10].

Skin Care and Basic Management

Regular use of emollients remains the cornerstone of AD management and plays a key role in restoring skin barrier function, reducing xerosis, and preventing disease flares [3,11]. Fragrance-free moisturizers with low water content are generally preferred.

The AAP 2025 update emphasized frequent use of thick moisturizers, gentle skin care, and short lukewarm bathing practices followed immediately by moisturization [10]. Ointments such as petrolatum may be preferred in children experiencing stinging with creams.

Avoidance of irritants and implementation of gentle skin care practices are essential components of long-term management. Common triggers include harsh soaps, detergents, fragrances, overheating, sweating, and low humidity environments [10].

Overemphasis on food allergy as the primary cause of eczema should be avoided. Unnecessary elimination diets may increase nutritional risks and potentially lead to loss of tolerance to previously tolerated foods [10].

Topical Therapies

Topical Corticosteroids

Topical corticosteroids remain first-line anti-inflammatory therapy for acute flares and maintenance treatment when appropriately used [4]. Selection of potency should be based on patient age, anatomical site, and disease severity.

Low-potency corticosteroids are generally preferred for the face, neck, and intertriginous areas, while moderate-to-high potency preparations may be required for thicker plaques on the trunk or extremities.

Intermittent proactive therapy using topical corticosteroids on previously affected areas may reduce flare frequency in recurrent disease [10].

Topical Calcineurin Inhibitors

Topical calcineurin inhibitors such as tacrolimus and pimecrolimus provide effective steroid-sparing options, particularly for sensitive areas including the face and flexures [5]. These agents are useful in long-term maintenance therapy and may reduce corticosteroid exposure.

Phosphodiesterase-4 Inhibitors

Crisaborole provides an additional nonsteroidal topical option for mild-to-moderate atopic dermatitis and has demonstrated favorable safety in pediatric populations [12].

Topical JAK Inhibitors

Ruxolitinib cream has emerged as an effective treatment for mild-to-moderate atopic dermatitis. Clinical studies demonstrated significant anti-inflammatory and antipruritic effects with favorable safety profiles in children and adolescents [13,14].

Infection Control and Adjunctive Therapies

Secondary bacterial infection, particularly with *Staphylococcus aureus*, may exacerbate disease severity. Appropriate infection control measures including targeted antimicrobial therapy when clinically indicated are important components of management.

Wet-wrap therapy may provide short-term benefit in severe flares by improving hydration and enhancing topical medication penetration.

Phototherapy represents an effective treatment option for refractory disease and may reduce disease severity when used appropriately [5]. Narrowband ultraviolet B therapy is most commonly utilized in selected pediatric patients.

Systemic and Targeted Therapies

In moderate-to-severe disease unresponsive to topical therapy, systemic treatment may be required.

Conventional Systemic Therapies

Traditional systemic agents including cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil may be considered in moderate-to-severe disease unresponsive to optimized topical management [15].

These therapies require careful monitoring because of potential toxicities including nephrotoxicity, hepatotoxicity, bone marrow suppression, and increased infection risk.

Dupilumab

Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling pathways, has significantly transformed the management of moderate-to-severe pediatric atopic dermatitis [16,17].

Clinical trials demonstrated substantial improvements in Eczema Area and Severity Index (EASI) scores, pruritus, sleep quality, and overall quality of life in children as young as six months of age [17].

Recent evidence also suggests that dupilumab may provide additional benefits beyond skin improvement, including reduction in psychiatric and sleep disorders and possible mitigation of atopic march progression in pediatric patients [18,19].

Furthermore, dupilumab has demonstrated positive effects on skin barrier restoration and normalization of ceramide composition [20].

Janus Kinase Inhibitors

Janus kinase inhibitors represent an important emerging therapeutic class offering rapid symptom relief through modulation of inflammatory signaling pathways.

Upadacitinib demonstrated significant improvement in refractory pediatric atopic dermatitis, including in dupilumab nonresponders, although monitoring for infection, anemia, and laboratory abnormalities remains important [21].

Although effective, systemic JAK inhibitors require careful consideration because of potential risks including infection, thromboembolic events, lipid abnormalities, and laboratory derangements.

Emerging Biologic Therapies

Emerging biologic therapies such as nemolizumab have demonstrated promising efficacy in improving both pruritus and disease severity in moderate-to-severe atopic dermatitis [22].

These therapies may further expand future treatment options and contribute to more individualized precision-based management strategies.

Psychosocial Impact and Quality of Life

Atopic dermatitis has substantial psychosocial effects on both patients and caregivers. Chronic pruritus, sleep disturbance, social embarrassment, anxiety, and depression contribute significantly to disease burden.

Recent studies demonstrated that effective biologic therapy may improve psychiatric symptoms and sleep-related disorders in patients with AD [18].

Recognition of mental health impact and incorporation of psychological support into management plans are increasingly emphasized in recent guidelines [10].

Future Directions

Emerging biologics and targeted therapies are transforming pediatric atopic dermatitis management. Ongoing research into immune modulation, microbiome-based therapies, skin barrier restoration, and precision medicine may further improve long-term outcomes and potentially reduce progression of the atopic march.

Future studies focusing on early intervention, biomarker-guided therapy, and long-term safety of biologic and JAK inhibitor therapies are likely to further refine pediatric AD management.

Conclusion

Pediatric atopic dermatitis requires a comprehensive, individualized, and evidence-based approach. Optimized skin care, topical anti-inflammatory therapies, patient education, and trigger avoidance remain foundational components of management.

Recent advances in biologic and targeted therapies have significantly improved outcomes in moderate-to-severe disease and expanded therapeutic possibilities for children with refractory disease.

Continued integration of evidence-based guideline recommendations and emerging therapies is essential for improving long-term outcomes, reducing disease burden, and enhancing quality of life in pediatric patients with atopic dermatitis.

Author Contributions

Dr Asim: Concept development, literature review, manuscript writing, final drafting.

Dr Mazher Iqbal: Critical review, clinical supervision, manuscript revision.

Conflicts of Interest

The authors declare that they have no competing interests.

Funding

No financial support was received for this study.

Ethical Approval

Not applicable, as this is a review article and does not involve human or animal subjects.

Acknowledgements

The authors would like to acknowledge the use of publicly available guidelines and literature in preparing this manuscript.

References

1. Weidinger S, Novak N. Atopic dermatitis. *Lancet*. 2016;387(10023):1109-1122.
2. Nutten S. Atopic dermatitis: global epidemiology and risk factors. *Ann Nutr Metab*. 2015;66(Suppl 1):8-16.
3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. *J Am Acad Dermatol*. 2014;70(2):338-351.
4. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for atopic dermatitis: management and treatment. *J Am Acad Dermatol*. 2014;71(2):327-349.
5. Wollenberg A, Christen-Zaech S, Taieb A, et al. ETFAD/EADV position paper on atopic dermatitis treatment. *J Eur Acad Dermatol Venereol*. 2018;32(5):657-682.
6. Chittock J, Kay L, Brown K, et al. Association between skin barrier development and early-onset atopic dermatitis: a longitudinal birth cohort study. *J Allergy Clin Immunol*. 2024;153(3):732-741.
7. Rapin A, Rehbindler EM, Macowan M, et al. The skin microbiome in the first year of life and its association with atopic dermatitis. *Allergy*. 2023;78(7):1949-1963.
8. Chiesa Fuxench ZC, Mitra N, Del Pozo D, et al. Risk of atopic dermatitis and the atopic march paradigm in children of mothers with atopic illnesses. *J Am Acad Dermatol*. 2024;90(3):561-568.
9. Schoch JJ, Anderson KR, Jones AE, et al. Atopic dermatitis: update on skin-directed management. *Pediatrics*. 2025;155(6):e2025071812.
10. American Academy of Pediatrics. Treating eczema (atopic dermatitis): AAP updates recommendations. *Pediatrics*. 2025.
11. National Institute for Health and Care Excellence (NICE). Atopic eczema in under 12s: diagnosis and management. 2023.
12. Su JC, Spelman LJ, Eichenfield LF, et al. Efficacy and safety of crisaborole in patients aged 3 months to 17 years with mild-to-moderate atopic dermatitis. *Pediatrics*. 2021;147(3_MeetingAbstract):302-303.
13. Papp K, Szepletowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3 randomized studies. *J Am Acad Dermatol*. 2021;85(4):863-872.
14. Leung DYM, Paller AS, Zaenglein AL, et al. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis. *Ann Allergy Asthma Immunol*. 2023;130(4):500-507

15. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic treatments for atopic dermatitis: systematic review. *J Allergy Clin Immunol*. 2018;142(6):1801-1815.
16. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335-2348.
17. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2022;400(10356):908-919.
18. Lin TL, Fan YH, Fan KS, et al. Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: a population-based cohort study. *Ann Allergy Asthma Immunol*. 2025;134(3):333-340.
19. Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy. *J Am Acad Dermatol*. 2024;91(3):466-473.
20. Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. *Allergy*. 2022;77(11):3388-3397.
21. Zhao M, Zhuang Y, Liang Y, et al. Upadacitinib for refractory paediatric atopic dermatitis: a real-world study on effectiveness and safety in dupilumab nonresponders. *Clin Exp Allergy*. 2024;54:694-696
22. Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate phase 3 trials. *Lancet*. 2024;404(10451):445-460.

Copyright: © 2026 All rights reserved by Asim M and Iqbal M. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.